Medigene AG Expands Patent Portfolio for its End-to-End Platform

Planegg/Martinsried, May 22, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today that the... | May 22, 2023

Related Keywords

Munich ,Bayern ,Germany ,China ,Hongsheng ,Hubei ,United States ,Japan ,Pamela Keck ,Planegg Martinsried ,Hongsheng Sciences ,Japan Patent Office ,Globenewswire Inc ,Prime Standard ,Helmholtz Munich ,Precision Pairing ,Programmed Death Ligand ,Medigene Ag Stock Exchange ,News ,Information ,Press Release ,Bay ,Medigene ,G ,N ,Platform ,Company ,Ocusing ,The ,Discovery ,End ,Development ,F , ,Fell ,Mmunotherapies ,Or ,Olid ,Nnounced ,Oday ,Hat Mdg1 De000a1x3w00 ,